APA (7th ed.) Citation

T, P., JJ, L., PK, C., DR, C., ME, B., YY, E., . . . SV, L. (2025). CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions. JCO precision oncology, 9, e2500221. https://doi.org/10.1200/PO-25-00221

Chicago Style (17th ed.) Citation

T, Patil, et al. "CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions." JCO Precision Oncology 9 (2025): e2500221. https://doi.org/10.1200/PO-25-00221.

MLA (9th ed.) Citation

T, Patil, et al. "CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions." JCO Precision Oncology, vol. 9, 2025, p. e2500221, https://doi.org/10.1200/PO-25-00221.